Condensed Consolidated Statements of Operations (unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Revenues:
Product sales, net	$ 1,510	$ 1,361
Research and development income	308	151
Licensing, royalty and other revenue	14	62
Total revenues	1,832	1,574
Costs and Expenses:
Cost of sales	1,366	1,241
Selling, general and administrative expenses	659	933
Product development and research expenses	471	379
Total costs and expenses	2,496	2,553
Operating loss	(664)	(979)
Interest income (expense), net	(71)	(55)
Net Loss	$ (735)	$ (1,034)
Basic and diluted loss per share (in Dollars per share)	$ (0.02)	$ (0.03)
Weighted average shares of common stock outstanding:
Basic and diluted (in Shares)	39,500,559	39,313,087